{"id":21161,"date":"2021-05-06T15:51:00","date_gmt":"2021-05-06T15:51:00","guid":{"rendered":"https:\/\/celonpharma.com\/?p=21161"},"modified":"2021-05-31T15:53:20","modified_gmt":"2021-05-31T15:53:20","slug":"current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/","title":{"rendered":"Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Current reports May 6, 2021<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br>Management Board of Celon Pharma S.A. The \u201cCompany\u201d informs that on May 5, 2021, it was entered into the register of the Regional Court for <a href=\"http:\/\/m.st\/\" target=\"_blank\" rel=\"noreferrer noopener\">the capital city<\/a> of Warsaw in Warsaw, 14th Economic Division of the National Court Register, entry in Section No. 8 of the KRS:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Adoption of a resolution on amending the Company&#8217;s Articles of Association and authorising the Company&#8217;s Management Board to increase the share capital within the authorized capital, with the Management Board&#8217;s possibility to exclude the pre-emptive rights issued within the authorized capital, in whole or in part, with the consent of the Supervisory Board. \u201cResolution No. 4\/2021\u201d);<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8211; an increase of PLN 200 000 of the share capital, in light of the adoption of resolution No. 7\/2021 by the Company\u2019s Extraordinary General Meeting on February 16, 2021, in order to implement Motivational Programs for the Members of the Board and other people of key significance to the Company, A-series subscription warrants, excluding the pre-emptive right of the existing shareholders, entitling to subscribe C-series shares and to increase the share capital by issuing C-series shares, excluding pre-emptive rights of the existing shareholders, and all the relevant amendments to the Company\u2019s Articles of Association.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Company\u2019s Management Board advises that the content of the resolutions adopted by the Company\u2019s Extraordinary General Meeting on February 16, 2021 was released to the public in the form of current report No. 9\/2021, and information about the registration of the relevant amendments to the Company\u2019s Articles of Association was released in current report No. 20\/2021.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Current reports May 6, 2021 Management Board of Celon Pharma S.A. The \u201cCompany\u201d informs that on May 5, 2021, it was entered into the register of the Regional Court for the capital city of Warsaw in Warsaw, 14th Economic Division of the National Court Register, entry in Section No. 8 of the KRS: Adoption of<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/\" title=\"ReadCurrent report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS)\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[46],"tags":[],"class_list":["post-21161","post","type-post","status-publish","format-standard","hentry","category-current-reports"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS) - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS) - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Current reports May 6, 2021 Management Board of Celon Pharma S.A. The \u201cCompany\u201d informs that on May 5, 2021, it was entered into the register of the Regional Court for the capital city of Warsaw in Warsaw, 14th Economic Division of the National Court Register, entry in Section No. 8 of the KRS: Adoption ofRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-06T15:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-31T15:53:20+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"Current report 21\\\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS)\",\"datePublished\":\"2021-05-06T15:51:00+00:00\",\"dateModified\":\"2021-05-31T15:53:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/\"},\"wordCount\":276,\"articleSection\":[\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/\",\"name\":\"Current report 21\\\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS) - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2021-05-06T15:51:00+00:00\",\"dateModified\":\"2021-05-31T15:53:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report 21\\\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS) - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/","og_locale":"en_US","og_type":"article","og_title":"Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS) - Celon Pharma","og_description":"Current reports May 6, 2021 Management Board of Celon Pharma S.A. The \u201cCompany\u201d informs that on May 5, 2021, it was entered into the register of the Regional Court for the capital city of Warsaw in Warsaw, 14th Economic Division of the National Court Register, entry in Section No. 8 of the KRS: Adoption ofRead more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/","og_site_name":"Celon Pharma","article_published_time":"2021-05-06T15:51:00+00:00","article_modified_time":"2021-05-31T15:53:20+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS)","datePublished":"2021-05-06T15:51:00+00:00","dateModified":"2021-05-31T15:53:20+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/"},"wordCount":276,"articleSection":["Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/","url":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/","name":"Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS) - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2021-05-06T15:51:00+00:00","dateModified":"2021-05-31T15:53:20+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/current-report-21-2021-entering-the-authorized-capital-and-the-increase-in-the-companys-share-capital-into-the-national-court-register-krs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Current report 21\/2021 \u2013 entering the authorized capital and the increase in the Company\u2019s share capital into the National Court Register (KRS)"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/21161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=21161"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/21161\/revisions"}],"predecessor-version":[{"id":21164,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/21161\/revisions\/21164"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=21161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=21161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=21161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}